Ranbaxy Laboratories has posted a slump in earnings for the first quarter, compared with the like, year-earlier period when it reaped the benefits of having exclusivity to sell a generic version of the blockbuster cholesterol-lowerer Lipitor in the USA. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/ranbaxy_earnings_sink_90_1004976Sanofi-Aventis has entered into a cancer collaboration with the Manchester, UK-based stem cell specialist Epistem. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/sanofi_signs_biomarker_pact_with_epistem_979410Biogen Idec has come first out of over 4,600 companies with a market cap of over $2 billion in a report assessing the most sustainable corporations in the world. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/biogen_tops_global_sustainability_list_970903Almirall has submitted a marketing authorisation application to the European Medicines Agency for aclidinium bromide for the treatment of chronic obstructive pulmonary disease. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/almirall_files_copd_drug_in_europe_980631Celltrion has received approval in its home market of South Korea for Herzuma, a biosimilar of Roche's blockbuster Herceptin. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/celltrion_gets_ok_for_herceptin_biosimilar_in_korea_1001368GlaxoSmithKline has decided not to pursue further worldwide development of Simplirix, an experimental vaccine intended to prevent genital herpes disease in women. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/gsk_pulls_simplirix_herpes_vaccine_982325Watson Pharmaceuticals is looking to expand its presence in Latin America by linking up with Brazil's Moksha8. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/watson_takes_stake_in_brazils_moksha8_982304Pfizer has been given the green light in Europe for Xiapex, a non-surgical treatment option for Dupuytren’s contracture, licensed from Auxilium Pharmaceuticals. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/pfizers_contracted_hand_treatment_gets_europe_ok_979513Creabilis, which is headquartered in Luxembourg, has raised 15 million euros in a series B funding led by Abbott Biotech Ventures. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/abbott_buys_into_luxembourgs_creabilis_980296Austrian biotechnology firm F-star has raised 15 million euros in a financing led by SR One, the corporate venture capital arm of GlaxoSmithKline. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/gsk_vc_fund_invests_in_austrias_f-star_979257
